Raimund H.
- Country
- Austria
- Department
- Neurology
Research Overview
- Phase III Randomized Double‑Blind Study of Fenebrutinib versus Teriflunomide for Efficacy and Safety in Adults with Relapsing Multiple Sclerosis
- Effect of Methylphenidate on the Time to Awakening in Patients with Coma Due to Acute Brain Injury: A Randomized, Double-Blind, Placebo-Controlled Trial
- A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus
Data & Insights
Has run more than one trial at 2 of 77 partner sites.
Specializations
Neurological Disorders
This investigator specializes in studying therapeutic approaches for refractory status epilepticus (RSE), focusing on severe seizure conditions that resist conventional treatments.
- Status Epilepticus Management
- Anticonvulsant Therapies
- Emergency Neurology
Their research extends to evaluating novel therapeutic interventions for patients with drug-resistant seizure conditions.
Critical Care Medicine
The investigator's work encompasses emergency neurological care with particular attention to treating severe seizure emergencies in critical care settings.
- Acute Seizure Management
- Emergency Response Protocols
- Critical Care Interventions
Their expertise includes evaluating intravenous therapeutic options for emergency neurological conditions.
Treatment Innovation
The investigator focuses on advancing novel therapeutic approaches for treating resistant seizure disorders, particularly exploring new medication options.
- Drug Safety Assessment
- Treatment Tolerability
- Standard of Care Enhancement
Their research aims to expand treatment options for patients with difficult-to-treat seizure conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.